NASDAQ:MNPR Monopar Therapeutics (MNPR) Stock Forecast, Price & News $0.58 +0.01 (+1.30%) (As of 05:19 PM ET) Add Compare Share Share Today's Range$0.55▼$0.6050-Day Range$0.57▼$0.8752-Week Range$0.53▼$4.88Volume6,049 shsAverage Volume194,893 shsMarket Capitalization$8.18 millionP/E RatioN/ADividend YieldN/APrice Target$11.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Monopar Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside1,888.3% Upside$11.33 Price TargetShort InterestHealthy1.13% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.44Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.76) to ($0.62) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.49 out of 5 stars 3.4 Analyst's Opinion Consensus RatingMonopar Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.33, Monopar Therapeutics has a forecasted upside of 1,888.3% from its current price of $0.57.Amount of Analyst CoverageMonopar Therapeutics has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.13% of the float of Monopar Therapeutics has been sold short.Short Interest Ratio / Days to CoverMonopar Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Monopar Therapeutics has recently decreased by 33.02%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMonopar Therapeutics does not currently pay a dividend.Dividend GrowthMonopar Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MNPR. Previous Next 3.0 News and Social Media Coverage News SentimentMonopar Therapeutics has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Monopar Therapeutics this week, compared to 1 article on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Monopar Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders41.60% of the stock of Monopar Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 6.18% of the stock of Monopar Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Monopar Therapeutics are expected to grow in the coming year, from ($0.76) to ($0.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Monopar Therapeutics is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Monopar Therapeutics is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMonopar Therapeutics has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Monopar Therapeutics (NASDAQ:MNPR) StockMonopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.Read More MNPR Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MNPR Stock News HeadlinesSeptember 28, 2023 | americanbankingnews.comShort Interest in Monopar Therapeutics Inc. (NASDAQ:MNPR) Decreases By 33.0%September 5, 2023 | finance.yahoo.comMonopar to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceSeptember 28, 2023 | Micro-Cap Stock Trader (Ad)U.S. drive to onshore battery supply chains could create big winners in lithiumInvestor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsSeptember 5, 2023 | finance.yahoo.comMonopar to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 10, 2023 | finance.yahoo.comMonopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent DevelopmentsAugust 8, 2023 | finance.yahoo.comMonopar Provides Encouraging Camsirubicin Clinical Data UpdateAugust 8, 2023 | finance.yahoo.comMonopar Provides Encouraging Camsirubicin Clinical Data UpdateJuly 11, 2023 | finance.yahoo.comMonopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of SingaporeSeptember 28, 2023 | Micro-Cap Stock Trader (Ad)Unlock the treasure on Mount Olympus with this little-known mining stock.Investor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsJuly 11, 2023 | finance.yahoo.comMonopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of SingaporeJune 21, 2023 | finance.yahoo.comMonopar to Participate in the Radiopharma Forum by the Lake 2023June 14, 2023 | finance.yahoo.comMonopar to Participate in the Maxim Group’s Healthcare Virtual ConferenceJune 1, 2023 | msn.comHC Wainwright & Co. Reiterates Monopar Therapeutics (MNPR) Buy RecommendationJune 1, 2023 | finance.yahoo.comMonopar Announces Encouraging Camsirubicin Phase 1b Trial UpdateJune 1, 2023 | finance.yahoo.comMonopar Announces Encouraging Camsirubicin Phase 1b Trial UpdateMay 29, 2023 | finance.yahoo.comMonopar Therapeutics Inc. (MNPR) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?May 15, 2023 | markets.businessinsider.comExpert Ratings for Monopar TherapeuticsMay 15, 2023 | msn.comHC Wainwright & Co. Maintains Monopar Therapeutics (MNPR) Buy RecommendationMay 15, 2023 | markets.businessinsider.comMonopar Therapeutics Inc (MNPR) Gets a Buy from H.C. WainwrightMay 13, 2023 | investing.comMonopar Therapeutics (MNPR) Earnings Dates & ReportsMay 11, 2023 | marketwatch.com10-Q: MONOPAR THERAPEUTICSMay 11, 2023 | finance.yahoo.comMonopar Therapeutics Reports First Quarter 2023 Financial Results and Recent DevelopmentsMay 11, 2023 | finanznachrichten.deMonopar Therapeutics Inc.: Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent DevelopmentsMay 11, 2023 | finance.yahoo.comMonopar Therapeutics Reports First Quarter 2023 Financial Results and Recent DevelopmentsMarch 30, 2023 | msn.comMaxim Group Downgrades Monopar Therapeutics (MNPR)March 29, 2023 | finanznachrichten.deMonopar Therapeutics Inc.: Monopar Announces Result of Interim Analysis of Phase 2b/3 VOICE Trial Evaluating Validive for Severe Oral MucositisMarch 28, 2023 | marketwatch.comMonopar Therapeutics Shares Plumb New Lows After Validive Failure >MNPRSee More Headlines Receive MNPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Monopar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MNPR Company Calendar Last Earnings8/10/2023Today9/28/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MNPR CUSIPN/A CIK1645469 Webwww.monopartx.com Phone847-388-0349FaxN/AEmployees11Year Founded2014Price Target and Rating Average Stock Price Forecast$11.33 High Stock Price Forecast$24.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+1,862.5%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,520,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-100.91% Return on Assets-79.73% Debt Debt-to-Equity RatioN/A Current Ratio4.12 Quick Ratio4.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.78 per share Price / Book0.74Miscellaneous Outstanding Shares14,160,000Free Float8,268,000Market Cap$8.18 million OptionableNot Optionable Beta0.93 Social Links The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Chandler D. Robinson M.B.A. (Age 39)M.D., M.Sc., MBA, MSc, Co-Founder, CEO, Pres & Director Comp: $708.12kMs. Kim R. Tsuchimoto CPA (Age 60)CFO, Sec., Treasurer & Director Comp: $350.55kMr. Andrew J. Cittadine M.B.A. (Age 51)Chief Operating Officer Comp: $390.41kDr. Patrice P. Rioux M.D. (Age 72)Ph.D., Acting Chief Medical Officer Key CompetitorsGalera TherapeuticsNASDAQ:GRTXNeuroSense TherapeuticsNASDAQ:NRSNSunshine BiopharmaNASDAQ:SBFMBionomicsNASDAQ:BNOXLexaria BioscienceNASDAQ:LEXXView All CompetitorsInsidersAndrew CittadineBought 6,053 shares on 11/14/2022Total: $18,159.00 ($3.00/share)View All Insider Transactions MNPR Stock - Frequently Asked Questions Should I buy or sell Monopar Therapeutics stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Monopar Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MNPR shares. View MNPR analyst ratings or view top-rated stocks. What is Monopar Therapeutics' stock price forecast for 2023? 5 Wall Street analysts have issued twelve-month price targets for Monopar Therapeutics' stock. Their MNPR share price forecasts range from $2.00 to $24.00. On average, they expect the company's share price to reach $11.33 in the next twelve months. This suggests a possible upside of 1,862.5% from the stock's current price. View analysts price targets for MNPR or view top-rated stocks among Wall Street analysts. How have MNPR shares performed in 2023? Monopar Therapeutics' stock was trading at $2.37 at the beginning of the year. Since then, MNPR shares have decreased by 75.6% and is now trading at $0.5775. View the best growth stocks for 2023 here. Are investors shorting Monopar Therapeutics? Monopar Therapeutics saw a decline in short interest in September. As of September 15th, there was short interest totaling 64,700 shares, a decline of 33.0% from the August 31st total of 96,600 shares. Based on an average daily trading volume, of 250,500 shares, the days-to-cover ratio is currently 0.3 days. Approximately 1.1% of the company's shares are short sold. View Monopar Therapeutics' Short Interest. When is Monopar Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our MNPR earnings forecast. How were Monopar Therapeutics' earnings last quarter? Monopar Therapeutics Inc. (NASDAQ:MNPR) released its quarterly earnings results on Thursday, August, 10th. The company reported ($0.16) earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.03. What other stocks do shareholders of Monopar Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Monopar Therapeutics investors own include Entasis Therapeutics (ETTX), Fulcrum Therapeutics (FULC), Sorrento Therapeutics (SRNE), Akero Therapeutics (AKRO), Chimerix (CMRX), Trevena (TRVN), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD) and Aquestive Therapeutics (AQST). When did Monopar Therapeutics IPO? (MNPR) raised $9 million in an initial public offering on Thursday, December 19th 2019. The company issued 1,100,000 shares at a price of $8.00 per share. JonesTrading served as the underwriter for the IPO and Arcadia Securities was co-manager. What is Monopar Therapeutics' stock symbol? Monopar Therapeutics trades on the NASDAQ under the ticker symbol "MNPR." How do I buy shares of Monopar Therapeutics? Shares of MNPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Monopar Therapeutics' stock price today? One share of MNPR stock can currently be purchased for approximately $0.58. How much money does Monopar Therapeutics make? Monopar Therapeutics (NASDAQ:MNPR) has a market capitalization of $8.18 million. The company earns $-10,520,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis. Does Monopar Therapeutics have any subsidiaries? The following companies are subsidiares of Monopar Therapeutics: Monopar Therapeutics Pty Ltd, and Monopar Therapeutics SARL.Read More How can I contact Monopar Therapeutics? Monopar Therapeutics' mailing address is 1000 SKOKIE BLVD SUITE 350, WILMETTE IL, 60091. The official website for the company is www.monopartx.com. The company can be reached via phone at 847-388-0349 or via email at info@monopartx.com. This page (NASDAQ:MNPR) was last updated on 9/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monopar Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.